Introduction
Since 1997, the Advisory Committee on Immunization Practices (ACIP) has recommended the routine vaccination of pregnant women with trivalent inactivated influenza vaccine (TIV) after the first trimester of pregnancy. This recommendation was expanded in 2004 to include all trimesters of pregnancy. 1 All previously published studies of pregnant women who were administered with TIV have reported this vaccine as safe during all stages of pregnancy. [2] [3] [4] Christian et al. explained the reason for this record of safety: 'The inflammatory response elicited by TIV is substantially milder and more transient than seen in infectious illness.' 5 Two frequently cited peer-reviewed reports on the safety of influenza vaccination during pregnancy did not reveal any adverse outcomes among 56 women 6 and 180 women. 7 Both these studies, which used 'no Thimerosal' influenza vaccines, had insufficient statistical power to adequately detect and assess complications due to the small sample size. A third follow-up safety study (conducted among 2291 pregnant women) cited by ACIP did not find increased childhood mortality associated with exposure to TIV in pregnancy. 3 However, fetal losses were not included in the analysis.
Based on the prior record of safety of TIV and the fact that the pandemic A-H1N1 vaccine shared the same licensure and manufacturing processes as the seasonal TIV, the ACIP recommended for the 2009/2010 influenza season that pregnant women receive the pandemic inactivated A-H1N1-virus vaccine in addition to the seasonal TIV (both produced by five approved vaccine manufacturers) during any trimester of pregnancy.
However, the safety and effectiveness of the pandemic (monovalent influenza) A-H1N1 vaccine had neither been previously established in pregnant women nor the combination of two different influenza vaccines ever tested in pregnant women. The A-H1N1 vaccine inserts from the various manufacturers contained this caution: ''It is also not known whether these vaccines can cause fetal harm when administered to pregnant women or can affect reproduction capacity. '' In October 2010, Moro et al. summarized that during 19 influenza seasons (1990/1991 through 2008/ 2009), there were a total of 17 spontaneous abortion (SAB) and 6 stillbirth (SB) reports following TIV in the Vaccine Adverse Event Reporting System (VAERS) database for an overall mean of 1.21 (23/ 19) fetal loss reports per year. This study's stated rate of fetal-loss reporting was 1.9 per 1 million (or 23/ 11,800,000) vaccinated pregnant women. 8 In a second study published 8 months following the first, Moro et al. noted 121 SAB and 19 SB reports or a total of 140 fetal-loss reports to VAERS during the first 5 months of the 2009/2010 influenza season. 9 This equates to greater than 57 reports per million (>140/ 2,437,113) vaccinated pregnant women. The ratio of the 140 fetal-loss reports during the incomplete 2009/ 2010 season to the 1.21 reports/year representing the mean of the 19 prior seasons, yields a 116-fold (140/ 1.21) increase in fetal-loss reports (SAB and SB) in the VAERS database. Moro et al. attributed this dramatic increase, in part, to reporting bias, citing a ''Weberlike effect.'' 9 The Weber effect is a temporal reporting pattern whereby the number of reported adverse events (AEs) for a new drug increases during the first 2 years of marketing and then subsequently declines, presumably reflecting decreased enthusiasm for reporting as AEs become well known.
Despite the statistically significant rate ratio (RR) of 29. 
Independent survey of fetal loss related to 2009/ 2010 A-H1N1 vaccine
An independent survey was conducted by the National Coalition of Organized Women (NCOW) via the Internet to serve as a second surveillance source for pregnant women suffering A-H1N1 fetal loss during the two-vaccine 2009/2010 influenza season. Eileen Dannemann, director of NCOW, oversaw this study and the data collected are summarized in the Results section. In response to a public service announcement delivered via several websites on the Internet, respondents contacted one of two study coordinators via phone or e-mail address. The respondents provided relevant details including (a) type of influenza vaccine received, (b) date of vaccination, (c) type of vaccine, (d) date of onset of symptom/symptoms, (e) date of SAB or miscarriage, (f) geographic location, (g) whether or not the AE was reported to VAERS, and (h) other miscellaneous comments.
Capture-recapture analysis was used to determine the reporting completeness of fetal-loss reporting using two ascertainment sources: (1) the NCOW survey and (2) the VAERS database. Ascertainmentcorrected fetal-loss report rates are computed by applying two-source capture-recapture methods to the number of reported fetal-loss incidents. [10] [11] [12] The estimator N* of the total fetal-loss incidents is given
where a is the number of fetal-loss incidents reported by both ascertainment sources, and b and c denote the number of fetal-loss incidents reported by the NCOW survey and VAERS ascertainment sources, respectively. When a > 6, there is 95% confidence that the theoretical bias is negligible; however, this does not account for any bias that might result from source dependencies or heterogeneity of the population within an ascertainment source. 13, 14 Since the distribution of the capture-recapture estimate is skewed in practice, to avoid misleading results associated with standard error estimates of result uncertainty, goodness-of-fit-based CIs were utilized. 15 Number of annual pregnancies and percentage of vaccinated pregnant women
The number of pregnancies given in Table 1 for each of the three consecutive influenza seasons was derived from Ventura et al. and was presumed to remain relatively constant at about 5,200,000. 16 While this same reference was used by Moro et al., Table 1 were taken from the National Health Interview Survey (NHIS) 17 and an unpublished National Health Family Survey (NHFS), respectively. These percentages are cited by Moro et al. 8, 9 A recent 2012 Centers for Disease Control and Prevention (CDC) report confirms the 43% uptake percentage during the 2009/2010 influenza season by reporting coverage among pregnant women as 47.1% for seasonal and 40.4% for A-H1N1 vaccine (mean 43.75%). 18 The 32% uptake percentage for pregnant women vaccinated in the 2010/2011 influenza season was reported by the CDC (and does not include the percentage of women vaccinated prior to or after pregnancy). 19 Qualitative and quantitative assessment of trends in fetal-loss reports
The VAERS reports were examined for evidence of temporal or location clustering. In addition, the rate of fetal-loss reported per million population by state was assessed to determine any trends in reporting Quantitative estimate of factor of increased reporting potentially due to Weber-like effect
If no Weber-like effect existed, that is there was no increased or enhanced AE reporting associated with the newly marketed pandemic A-H1N1 vaccine during the 2009/2010 influenza season, we would expect the number of VAERS reports resulting from administration of the seasonal TIV and pandemic A-H1N1 vaccine to be approximately equal. In other words, the ratio of AE reports for A-H1N1 to seasonal TIV would be 1:1. Any increase in the number of VAERS reports associated with A-H1N1 over the seasonal TIV would yield a ratio or factor greater than one -representing the possible effect of a Weber-like reporting bias. Such a Weber or Weber-like reporting bias would expect to be generally distributed among all VAERS reports -not only those describing pregnant women experiencing temporally related fetal loss but also those describing other AEs among nonpregnant females and males. VAERS reports of anaphylactic shock occurring the same day of administration of influenza vaccine served as a control to test the potential Weber-like reporting bias.
Results

VAERS reports
Although there was an approximate fourfold (43%/ Table 1 ).
Summary of the independent NCOW survey
The NCOW survey of fetal losses had a total of 72 respondents, 5 (7%) of which were excluded for the following reasons: 1 (1.4%) report of indirect H1N1 transmission to a child, which caused infection and miscarriage in a pregnant woman; 3 (4.2%) reports outside the United States (US); and 1 (1.4%) report with no adverse outcome. Of the 67 remaining instances, 62 (92.5%) and 5 (7.5%) reports of fetal demise were following A-H1N1 and seasonal TIV, respectively, A comparison of the mean elapsed time from administration of influenza vaccine to fetal demise and mean gestational age at time of fetal demise is given in Table 2 for those of the 174 VAERS cases and 67 NCOW survey respondents that provided sufficient information. There was no statistically significant difference in the distribution of fetal loss by trimester between the VAERS reports and NCOW survey respondents (w 2 ¼ 1.69; p ¼ 0.43; Table 3 ).
Ascertainment-corrected reports for the twovaccine 2009/2010 influenza season
Applying capture-recapture using 67 case reports from the NCOW survey, 174 case reports from VAERS, and 8 cases shared by both ascertainment sources, yields an overall reporting completeness for the two ascertainment sources of 17.6% based on an estimated ascertainment-corrected 1321 (95% CI: 815-2795) fetal-loss reports. Thus, the 174 VAERS fetal loss case reports represent 13.2% (174/1321) of (Table 4) .
The ages of the women in the fetal-loss reports indicated a reporting bias associated with older pregnant women (mean age 32 years) as has been previously observed. Table 5) .
Inspection of all influenza reports of males and females (shown in bold in Table 5 Use of an independent control AE group to isolate and independently estimate the potential size of a true Weber-like effect 
VAERS reports of fetal demise following administration of A-H1N1 vaccine and TIV
A recently published CDC morbidity and mortality weekly report 18 indicated that 28.5% of pregnant women were administered with both A-H1N1 vaccine and TIV. Since approximately 43% of pregnant women received at least one influenza vaccine (Table 1) , the majority of those vaccinated -66% (28.5/43%) -received a dose of both types of inactivated influenza vaccines.
Since the TIV became available early in the 2009/ 2010 influenza season, it was initially administered first followed then by the subsequent administration of a pandemic A-H1N1 vaccine when those inactivated 2009 A-H1N1 influenza vaccines became available. This probably partially accounts for the high 
Discussion
Capture-recapture estimates can lead to inaccurate and sometimes misleading results if the underlying assumptions are not met. 21 In epidemiological investigations, ascertainment sources often display dependence and heterogeneity of capture probabilities. 22 The major question individuals ask regarding capture-recapture is 'Will capture-recapture give you the truth?' That is, will it provide an extremely accurate estimate of the fetal loss incidence rates? Simply answered, no -it will not. When capture-recapture techniques are not utilized, the estimates presented in most epidemiologic studies are extremely poor, missing 10-90% of the cases, with a high degree of variation. 10, 11, 23, 24 Thus, often the disease incidence that is reported simply reflects the incomplete case ascertainment of the study and not the true incidence of the disease in the population. Therefore, the options are (a) not to use capturerecapture and report fetal loss from which the incidence rates are almost uninterpretable since such rates merely reflect the level of case ascertainment, (b) try to count every case of fetal loss, which is horrendously expensive and slow, or (c) utilize capturerecapture, which, depending on the degree to which the assumptions are satisfied, as a compromise, can be a reasonably accurate, quick, and inexpensive approach.
The estimated 13.2% reporting completeness of the VAERS fetal-loss case reporting is suggestive of a low fetal-loss reporting rate during the 2009/ 2010 influenza season rather than a high reporting completeness of AEs -such as might be caused by a Weber-like effect. Furthermore, the general level of reporting of fetal-loss reports was variable when adjusted by state population with 56% of states reporting 0-2 cases (mean 1 report/state) and 44% reporting >2 cases (mean 5.4 reports/state) with no clustering of reports. Moreover, the percentage of influenza vaccine-related reports to VAERS for females was similar for each of the consecutive influenza seasons. Finally, the fetal loss rate dramatically declined from 77. Based on respondents' comments to the NCOW survey in the 2009/2010 season, it is likely that the ascertainment-corrected rate of 535 fetal losses per million pregnant women vaccinated represents a significant underestimate during the two-vaccine 2009/2010 influenza season since health care professionals explained to patients 'the benefits of influenza vaccination outweighed the risks.' Medical literature reporting the mean rate of '1.9 fetal losses per million pregnant women vaccinated' for the previous 19 single-vaccine influenza seasons based on counts of VAERS reports that were not adjusted for under-ascertainment, 8 likely contributed to this perception of safety. Because both patient and health care professionals relied on a historical profile that was incomplete with respect to assessing fetal-demise reporting, a possible link to fetal demise following administration of influenza vaccine/vaccines during 2009/2010 was rarely contemplated or was considered highly unlikely and thus, more often than not, not reported.
The ratio of the 12,300 AE reports associated with A-H1N1 vaccine to the 7691 due to TIV is 1.60, which is similar to the ratio of 1.59 using female AE reports (Table 5) . If a Weber-like increase existed, a readily discernible AE, such as anaphylactic shock, should have generated at least a 1.6-fold increase in VAERS reports associated with the 'new' pandemic A-H1N1 vaccine; however, no such increase was found. This independent AE control group confirms that most of the observed 7.7-fold (170 A-H1N1 fetal-loss reports/22 TIV fetalloss reports) increase in fetal-loss reports associated with the administration of the 2009 A-H1N1 vaccine appears to be attributable to some type of toxicity effect rather than a 'new vaccine' Weber-like reporting effect.
When one or more Thimerosal-containing vaccines, including some formulations of the seasonal TIV and pandemic monovalent A-H1N1 vaccines are administered to a pregnant woman, the fetus is also indirectly exposed to mercury. In the following paragraphs, several peer-reviewed publications highlight the concerns that this mercury exposure poses.
A study using rabbits injected with Thimerosalcontaining radioactive mercury showed that from 1-h post-injection to 6 h, the level of radioactive mercury in the blood dropped over 75% while from 2 h postinjection to 6 h, there were significantly increased radioactivity levels in the fetal brain, liver, and kidney. 25 Thus, the rapid drop in blood mercury levels from Thimerosal injection is due to uptake by other organs of the body and not due to excretion. 26 Therefore, the implications by others of Thimerosal's safety based on shorter blood level half-lives 27 suffers from lack of a circumspect view regarding this process.
The linkage between Thimerosal and neurodevelopmental disorders is a concern because several studies have shown that children with autistic spectrum disorders (ASDs) have higher levels of mercury body burden than typically developing children. [28] [29] [30] [31] [32] [33] In addition, there is a positive correlation between mercury body burden and severity of ASD symptoms. [34] [35] [36] Direct measurement of injury in the brains of children with ASD reinforce this finding; there is a significant dosedependent positive correlation between oxidative stress markers (evidence of brain injury) and mercury levels in the brains of children with ASD. 37 The amount of mercury that accumulates in any given fetus and the severity of its impact depend upon several factors in addition to the maternal mercury exposure due to injected Thimerosal-containing inactivated influenza vaccines. Dental amalgams in pregnant women contribute to increased mercury burden in the developing fetus and newborn. [38] [39] [40] Also, the maternal-fetal genetic background can modulate fetal exposure to mercury; thus, certain gene variants influence mercury toxicokinetics causing the variable susceptibility that is observed with respect to mercury toxicity. 41 This variation in genetic susceptibility, combined with factors of diet and antibiotic use, can synergistically enhance mercury toxicity 42 and effectively preclude establishment of a safe mercury dosing level for all individuals. Moreover, the 0.1 mcg/kg/day reference dose that the Environmental Protection Agency (EPA) established as safe based on oral ingestion of mercury is not applicable for injected Thimerosal via vaccination since injection bypasses the absorption protection provided by the gastrointestinal system (which is also apparently dependent on the manner in which the fish or other mercury-containing food is prepared). 43 thereby delivering more of the toxic dose of mercury administered into the body.
Finally, Thimerosal has been found to be toxic at very low levels. For example, Parran et al. examined the effects of Thimerosal on cell death in a human neuroblastoma cell line. Following 48 h of a single dose of 4.35 nanomolar Thimerosal (or about 0.87 mcg/kg of mercury) over 50% of cells were dead. 44 Thus, it is biologically plausible that during the twovaccine 2009/2010 influenza season, when pregnant women were administered two Thimerosal-containing influenza vaccines each delivering 50 mcg of Thimerosal (or 25 mcg of mercury per dose), the fetus' mercury dose exceeded the EPAs reference dose (0.1 mcg of mercury/kg/day). This overexposure could be a significant contributing factor to some of the reported SABs and SBs. Moreover, the mercury in injected Thimerosal-containing vaccine doses has been found to preferentially bioaccumulate in the fetal tissues. 25 Table 6 demonstrates that depending upon the gestational age, the safety level of mercury (as specified by the EPA's reference dose) may be exceeded by several thousand fold for an early developing fetus during the first trimester to a factor of just over 1 at full-termeven for a single reduced Thimerosal vaccine dose presuming only 50% of the mercury (0.5 mcg) bioaccumulates in the fetus (Table 6 , fourth column labeled '1 mcg of Hg in the vaccine dose'). Recent studies have similarly described biologically plausible mechanisms associated with the synergistic toxicity associated with multiple vaccine doses administered to children aged <1 year. 48, 49 The bias in reporting of fetal loss by older women may be due, in part, to this cohort's previous experience with one or more normal pregnancies, free from maternal complications when they did not receive an influenza vaccine during pregnancy, and thus, having more birthing experience than younger, first-time pregnant women. Also, this cohort may have a higher body burden of mercury from the bioaccumulation of mercury from dental amalgams, diet, prior doses of Thimerosal-containing vaccines, and other drugs.
The Internet survey was self-administered, thus, the responses are subject to reporting error since pregnancy and vaccination status were not validated by a medical record review. There may also be selection bias since women without Internet access would be excluded from referencing the Public Service announcement (and the survey). Nevertheless, Internet panels have been useful as surveillance data sources for postseason evaluation of influenza vaccination among pregnant women. 19 
Conclusion
The 1.8-fold increase in female AEs reports to VAERS following administration of pandemic A-H1N1 vaccine relative to seasonal TIV in the 2009/2010 influenza season is too small of a Weber-like increased reporting effect to account for the more than 40-fold increase in fetal-loss reports. Thus, the concomitant administration of the seasonal influenza and pandemic A-H1N1 vaccines during 2009/2010 suggests a synergistic toxicity and a statistically significant higher rate of fetal loss reporting relative to the single-dose seasons. When capture-recapture is applied to the two-vaccine 2009/2010 The VAERS rates of 6.8 and 12.6 fetal-loss reports per million women vaccinated for those singlevaccine seasons may provide health care professionals with a sense that influenza vaccines administered during pregnancy are relatively safe, when, in reality, these rates merely reflect the low level of case ascertainment associated with VAERS and thus, grossly underestimate the true rates encountered in the US population. Just because a single vaccine has been tested and considered safe does not imply there will not be a synergistic fetal toxicity effect associated with the administration of two or more Thimerosal-containing vaccines to a pregnant women and/or a synergistic toxicity effect from the combination of the biologically active components contained in concomitantly administered vaccines.
In addition, because of the order of magnitude increase in fetal-loss report rates, from 6. Additional research concerning potential synergistic risk factors associated with the administration of Thimerosal-containing vaccines is warranted, and the exposure-effect association should be verified in further toxicological and case-control studies.
